Nielsen Pays $2.15B for DoubleVerify to Bolster Media Intelligence Offering
The deal underscores the importance of verifying media quality, efficacy and outcomes in an increasingly digital world.
Nielsen has acquired DoubleVerify, adding the AI-powered audience quality, optimization and measurement software platform to its own offerings spanning the media lifecycle.
The media giant is shelling out $13.60 in cash per DoubleVerify share, adding up to an estimated enterprise value of $2.15 billion, according to Nielsen’s deal announcement.
DoubleVerify’s software uses trusted data and AI technology to verify audience and inventory data, help brands dynamically adapt their bidding strategies in programmatic campaigns and track performance and outcomes across channels.
Bringing DoubleVerify’s technology under the Nielsen umbrella is meant to “extend our capabilities deeper into the digital media industry, ensuring that the spend flowing between buyers and sellers is reaching real people in brand-suitable environments, through verified channels,” as Nielsen CEO Karthik Rao said in the announcement.
Rao added that the expanded capabilities will allow Nielsen to serve as “a truly independent, end-to-end partner” in media intelligence and delivery for brands, agencies, publishers and platforms.
The acquisition is expected to close by the first quarter of next year, after which DoubleVerify will operate as an independent entity within Nielsen.
solli’s Final Thoughts
Pharma media should take note of how Nielsen’s move to fold DoubleVerify into its existing offerings indicates a growing expectation for partners and platforms to run the full gamut of supporting media quality, measurement and outcomes attribution.
Surging investments in digital channels and AI-powered planning are putting greater pressure on pharma marketers to prove validity, efficacy and compliance in every impression.
If Nielsen and DoubleVerify are able to preserve trust while combining all of those signals, the deal could ultimately raise the bar for accountability across media buying in pharma and beyond.
